Research and Markets: Global Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Pipeline Review, H2 2015 - 9 Companies & 21 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/zfq4lg/severe_acute) has announced the addition of the "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• CEL-SCI Corporation
• GeneCure LLC
• Humabs BioMed SA
• Kineta, Inc.
• Myelo Therapeutics GmbH
• Nanotherapeutics, Inc.
• Novavax, Inc.
• Phelix Therapeutics, LLC
• Protein Sciences Corporation

Drug Profiles

• CEL-1000
• D-3252
• Drugs to Inhibit Cathepsin L for Infectious Diseases
• FDX-000
• IKT-014
• LCA-60
• ML-188
• MMCatLMC
• Monoclonal Antibody for SARS Virus Infections
• Myelo-001
• rOAS
• SARS vaccine
• SARS vaccine
• SARS-CoV Vaccine
• severe acute respiratory syndrome vaccine
• severe acute respiratory syndrome vaccine + middle east respiratory syndrome vaccine
• Small Molecule for SARS
• Small Molecule to Inhibit Cathepsin L for SARS and Ebola Viral Infections
• SSYA-10001
• Synthetic Peptide to Target Spike Protein for SARS Infection
• thiocarbazate

For more information visit http://www.researchandmarkets.com/research/zfq4lg/severe_acute

View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005454/en/